In May 2023, the US Food and Drug Administration (FDA) approved the first vaccines for the prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) for use in adults aged ≥60 years: 1 manufactured by GSK (Arexvy)1 and 1 by Pfizer (Abrysvo).2 In July 2023, FDA approved nirsevimab (Beyfortus, Sanofi, and AstraZeneca), a long-acting monoclonal antibody for passive immunization to prevent RSV-associated LRTD among infants and children aged <24 months.3 In August 2023, FDA approved the Pfizer RSV vaccine for pregnant persons, with administration indicated at 32 to 36 weeks’ gestation to prevent RSV-associated LRTD and severe LRTD in infants aged <6 months.2 GSK RSV vaccine is not approved for use during pregnancy.1 In August 2023, the Advisory Committee on Immunization Practices and the Centers for Disease Control and Prevention (CDC) recommended nirsevimab for all infants aged <8 months who are born during...

You do not currently have access to this content.